Gottlieb Blames Plans, PBMs For Lack Of Biosimilar Uptake

By Rachel Cohrs
March 20, 2019 at 12:19 PM
Outgoing FDA Commissioner Scott Gottlieb on Tuesday (March 19) blamed insurers and pharmacy benefit managers for slower biosimilar uptake in the United States than in Europe. The rebate system favors brand biopharmaceuticals and PBMs are failing to steer patients toward biosimilars, Gottlieb said at a Brookings Institution event. Plans are reluctant to give biosimilars favorable formulary placement for fear of losing rebates for brand biologics, Gottlieb said. “I think the plans should look beyond the next quarter and recognize that...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.